A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

Running, not enrolling · Phase 1

Conditions studied: Healthy

In brief

The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.

Key facts

Study ID

NCT07619443

Run by

Merck Sharp & Dohme LLC

People needed

30

Starts

2026-07-01

Expected to finish

2026-09-12

Last updated by the study team

2026-08-05

Who can join

Age: 19 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The main inclusion criteria include but are not limited to the following:
• Is in good health before randomization
• Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2, inclusive

You may not qualify if…

• The main exclusion criteria include but are not limited to the following:
• Has a history or presence of clinically significant medical or psychiatric condition or disease
• Has a history of cancer

Where it is running

• Celerion ( Site 0001) — Lincoln, Nebraska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.